Tamoxifen
What's New
Last Posted: Mar 11, 2021
- Breast Cancer Patients at Increased Risk of Developing Type II Endometrial Cancer: Relative and Absolute Risk Estimation and Implications for Counseling.
Portela Sara et al. Cureus 2021 13(1) e12981 - The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer.
Nitz Ulrike et al. Therapeutic advances in medical oncology 2020 121758835920973130 - Young women's decision-making and experience of using tamoxifen to reduce BRCA1/2 breast cancer risk: a qualitative study.
Forrest Laura E et al. Psycho-oncology 2020 Oct - Molecular Assays to Determine Optimal Duration of Adjuvant Endocrine Therapy in Breast Cancer.
Anandan Apoorva et al. Current treatment options in oncology 2020 Aug 21(10) 84 - Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer.
Ueno Takayuki et al. Chinese clinical oncology 2020 Jun 9(2) 35 - PHARMACOGENOMICS OF ANTI-CANCER DRUGS: personalizing the CHOICE AND dose TO managE drug response.
Carr Daniel F et al. British journal of clinical pharmacology 2020 Jun - Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen.
Chan Carmen W H et al. Journal of cancer research and clinical oncology 2020 Apr - Breast cancer risk in young women in the national breast screening programme: implications for applying NICE guidelines for additional screening and chemoprevention.
Evans D Gareth et al. Cancer prevention research (Philadelphia, Pa.) 2014 Oct 7(10) 993-1001 - Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
Phillips Kelly-Anne et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013 Sep 31(25) 3091-9 - Germline variant burden in multidrug resistance transporters is a therapy-specific predictor of survival in breast cancer patients.
Xiao Qingyang et al. International journal of cancer 2020 Feb
More
About PGx PHGKB
PGx PHGKB is an online, continuously updated, searchable database of published scientific literature, CDC and NIH resources, and other materials that address the translation of genomic and other precision health discoveries into improved health care and prevention related to medications....more
Content Summary
- COVID-19 (1)
- Human Genome Epidemiologic Studies (308)
- GWAS Studies (3)
- Human Genomics Translation/Implementation Studies (44)
- Genomic Tests Evidence Synthesis (17)
- Genomic Tests Guidelines (6)
- Tier-Classified Guidelines (5)
- State Public Health Genomics Programs (4)
- Reviews/Commentaries (32)
- Tools/Methods (2)
Common PGx Related Topics
Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
- Page last reviewed:Oct 1, 2020
- Page last updated:Apr 26, 2021
- Content source: